Exact Sciences Strengthens Evidence Supporting Cologuard® and Oncotype DX® Tests and Deep Oncology Pipeline with Multiple Data Presentations at ASCO 2021
"Exact Sciences is changing the way we detect and treat cancer.
- "Exact Sciences is changing the way we detect and treat cancer.
- Building on the success of Cologuard and Oncotype tests, Exact Sciences is investing in its product pipeline to support patients throughout their cancer diagnosis and treatment.
- For more information, please visit the company\'s website at www.exactsciences.com , follow Exact Sciences on Twitter @ExactSciences , or find Exact Sciences on Facebook.\nNOTE: Oncotype, Oncotype DX, Oncotype DX Breast Recurrence Score, Oncotype DX Breast DCIS Score, Oncotype DX Genomic Prostate Score, Oncotype MAP Pan-Cancer Tissue, and Oncotype DX AR-V7 Nucleus Detect are trademarks or registered trademarks of Genomic Health, Inc.
- Exact Sciences and Cologuard are trademarks or registered trademarks of Exact Sciences Corporation.